TapewireFind a company

person · Reporting owner

Burnett Patrick

Disclosed activity across 2 companies

Tapewire entity
20722
SEC CIK
0001741987

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236See RemarksAugust 19, 2026August 21, 2026
Verrica Pharmaceuticals Inc.VRCA · Entity 6823Chief Medical OfficerFebruary 27, 2020March 02, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcutis Biotherapeutics, Inc.

Report date August 19, 2026 · Filed August 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect117,592 Reported balance After 2026-08-19 transaction · row 1
1 source row

Row 1 · 2026-08-19 · Sale · Disposed 1,697 · Balance 117,592

F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Verrica Pharmaceuticals Inc.

Report date February 27, 2020 · Filed March 02, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2030-02-26Direct55,000 Reported balance After 2020-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-02-27 · Grant · Acquired 55,000 · Balance 55,000

F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 19, 2026 Filed Aug 21, 2026 20:08 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 1,697 $27.00 $45,819.00
Disclosure

SEC source: 0001628280-26-058420 · wk-form4_1787342879.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,592

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Read SEC document
August 12, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 6,700 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · derivative · entry 6

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,750

Underlying: Common Stock · 6,700 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F1 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
August 12, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 6,700 $26.08 $174,767.49
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 4

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,289

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 12, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 6,700 $3.64 $24,388.00
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
August 11, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 8,300 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · derivative · entry 5

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,450

Underlying: Common Stock · 8,300 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F1 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
August 11, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 8,300 $26.52 $220,129.28
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,289

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 11, 2026 Filed Aug 14, 2026 00:06 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 8,300 $3.64 $30,212.00
Disclosure

SEC source: 0001628280-26-056898 · wk-form4_1786666006.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
August 03, 2026 Filed Aug 6, 2026 01:42 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 955 $26.12 $24,941.54
Disclosure

SEC source: 0001628280-26-053755 · wk-form4_1785980541.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,289

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
May 11, 2026 Filed May 13, 2026 23:42 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 222 $21.05 $4,673.10
Disclosure

SEC source: 0001741987-26-000004 · wk-form4_1778715752.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,244

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Read SEC document
May 04, 2026 Filed May 6, 2026 22:15 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 684 $23.61 $16,149.65
Disclosure

SEC source: 0001741987-26-000002 · wk-form4_1778105713.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,466

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 181 $25.91 $4,690.43
Disclosure

SEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 4

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,150

F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

F6 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.71 to $26.70, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F7 · balance_after: Due to a scrivener's error on the Reporting Person's Form 4s filed since November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadvertently understated the Reporting Person's ownership by a range of 18 to 36 shares. The corrected number of shares beneficially owned is reflected in this Form 4.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 6,106 $25.16 $153,629.40
Disclosure

SEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,295

F4 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 27, 2026 Filed Mar 4, 2026 01:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 GrantStock Option (right to buy) · Derivative 77,000 $0.00 Strike: $26.97 $0.00
Disclosure

SEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · derivative · entry 5

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,000

Underlying: Common Stock · 77,000 shares

Expires 2036-02-27

F8 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
February 27, 2026 Filed Mar 4, 2026 01:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 GrantCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001628280-26-014324 · wk-form4_1772588506.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 127,401

F3 · kind: Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
February 04, 2026 Filed Feb 5, 2026 00:30 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 9,794 $25.81 $252,747.88
Disclosure

SEC source: 0001628280-26-005571 · wk-form4_1770251397.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 80,651

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.58 to $26.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 02, 2026 Filed Feb 5, 2026 00:30 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 3,675 $25.50 $93,706.62
Disclosure

SEC source: 0001628280-26-005571 · wk-form4_1770251397.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,445

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
January 05, 2026 Filed Jan 7, 2026 22:46 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,490 $28.98 $72,165.68
Disclosure

SEC source: 0001628280-26-001241 · wk-form4_1767826005.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,120

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.77 to $29.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 31, 2025 Filed Jan 2, 2026 23:12 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 1,156 $29.39 $33,974.03
Disclosure

SEC source: 0001628280-26-000209 · wk-form4_1767395540.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,610

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020.

F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020.

F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $29.0829 to $29.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 31, 2025 Filed Jan 2, 2026 23:12 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 541 $28.81 $15,586.21
Disclosure

SEC source: 0001628280-26-000209 · wk-form4_1767395540.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,766

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020.

F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units, granted on August 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.08 to $29.08, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 22:53 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 11,500 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · derivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,750

Underlying: Common Stock · 11,500 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 22:53 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 11,500 $28.94 $332,851.40
Disclosure

SEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,307

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $28.61 to $29.20, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
December 15, 2025 Filed Dec 17, 2025 22:53 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 11,500 $3.64 $41,860.00
Disclosure

SEC source: 0001741987-25-000010 · wk-form4_1766012033.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · balance_after: Due to a scrivener's error on the Reporting Person's Form 4 filed on November 5, 2025, the number of shares of common stock beneficially owned by the Reporting Person was inadvertently overstated by 18 shares. The corrected number of shares beneficially owned is reflected in this Form 4.

Read SEC document
November 06, 2025 Filed Nov 10, 2025 22:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 17,250 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · derivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,250

Underlying: Common Stock · 17,250 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
November 06, 2025 Filed Nov 10, 2025 22:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 17,250 $24.18 $417,144.68
Disclosure

SEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,325

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.79 to $24.4493, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
November 06, 2025 Filed Nov 10, 2025 22:41 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 17,250 $3.64 $62,790.00
Disclosure

SEC source: 0001741987-25-000008 · wk-form4_1762814517.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

Read SEC document
November 05, 2025 Filed Nov 5, 2025 23:57 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 3,864 $23.72 $91,643.26
Disclosure

SEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,325

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.52 to $23.865, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
November 03, 2025 Filed Nov 5, 2025 23:57 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 15 $25.40 $381.00
Disclosure

SEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,189

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Read SEC document
November 03, 2025 Filed Nov 5, 2025 23:57 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,607 $24.71 $64,425.23
Disclosure

SEC source: 0001741987-25-000005 · wk-form4_1762387044.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,204

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.31 to $25.31, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 01:32 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,438 $15.57 $37,968.92
Disclosure

SEC source: 0001787306-25-000130 · wk-form4_1755826361.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,811

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F3 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.43 to $15.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 19, 2025 Filed Aug 22, 2025 01:32 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 1,750 $16.16 $28,280.70
Disclosure

SEC source: 0001787306-25-000130 · wk-form4_1755826361.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,249

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units.

F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.87 to $16.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 08, 2025 Filed Aug 12, 2025 21:04 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 3,847 $14.03 $53,988.41
Disclosure

SEC source: 0001787306-25-000126 · wk-form4_1755032693.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,999

F1 · kind: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026.

F1 · shares: The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024 by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.992 to $14.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
August 04, 2025 Filed Aug 5, 2025 22:28 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,622 $14.33 $37,564.35
Disclosure

SEC source: 0001787306-25-000118 · wk-form4_1754432935.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,846

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.965 to $14.675, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 14, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 5,750 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · derivative · entry 6

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,500

Underlying: Common Stock · 5,750 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
July 14, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 5,750 $15.07 $86,653.65
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 4

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,468

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F3 · price: The transaction was executed in multiple trades in prices ranging from $15.00 to $15.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 14, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 5,750 $0.00 $0.00
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

Read SEC document
July 10, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 23,000 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · derivative · entry 5

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,250

Underlying: Common Stock · 23,000 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F4 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
July 10, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 23,000 $15.05 $346,046.50
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,468

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The transaction was executed in multiple trades in prices ranging from $15.00 to $15.125, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
July 10, 2025 Filed Jul 14, 2025 20:02 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 23,000 $0.00 $0.00
Disclosure

SEC source: 0001787306-25-000106 · wk-form4_1752523337.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 138,468

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

Read SEC document
May 08, 2025 Filed May 9, 2025 23:45 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 3,871 $13.59 $52,623.15
Disclosure

SEC source: 0002065881-25-000007 · wk-form4_1746834341.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,468

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
May 02, 2025 Filed May 5, 2025 21:20 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,597 $15.19 $39,442.46
Disclosure

SEC source: 0001787306-25-000084 · wk-form4_1746480007.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,339

F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") granted on February 13, 2024.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.75 to $15.5519, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 12,242 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · derivative · entry 7

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,250

Underlying: Common Stock · 12,242 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 12,242 $15.04 $184,107.44
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 5

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,936

F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.1429, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 12,242 $0.00 $0.00
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 4

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,178

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionStock Option (right to buy) · Derivative 5,008 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · derivative · entry 6

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,492

Underlying: Common Stock · 5,008 shares

Expires 2034-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 5,008 $15.10 $75,631.32
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,936

F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

F4 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 Exercise / conversionCommon Stock 5,008 $0.00 $0.00
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 2

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,944

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document
March 13, 2025 Filed Mar 17, 2025 20:51 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 44,153 $14.97 $660,771.72
Disclosure

SEC source: 0001787306-25-000045 · wk-form4_1742244710.xml · nonDerivative · entry 1

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,936

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.6545 to $15.35, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 04, 2025 Filed Mar 5, 2025 00:44 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 954 $13.28 $12,673.03
Disclosure

SEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 4

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,089

F4 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2021.

F5 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.28 to $13.99, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 00:44 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 SaleCommon Stock 2,819 $13.03 $36,734.67
Disclosure

SEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · nonDerivative · entry 3

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,043

F2 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, granted on March 3, 2022 and March 2, 2023.

F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.6902 to $13.83, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Read SEC document
February 28, 2025 Filed Mar 5, 2025 00:44 UTC Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 GrantStock Option (right to buy) · Derivative 43,000 $0.00 Strike: $13.69 $0.00
Disclosure

SEC source: 0001787306-25-000043 · wk-form4_1741135437.xml · derivative · entry 6

Burnett Patrick · CIK 0001741987 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,000

Underlying: Common Stock · 43,000 shares

Expires 2035-02-28

F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.